Lung Function Key to COVID-19 Outcomes in Cystic Fibrosis Transplant Patients

A new multinational study sheds light on how cystic fibrosis transplant recipients fare when infected with SARS-CoV-2. Researchers analyzed data from 526 patients across 19 countries, focusing on hospitalization, death, and post-infection lung function changes.

The findings show transplant timing has little impact on disease severity. Instead, baseline lung function-measured by ppFEV1-was strongly linked to outcomes. Patients with higher lung function had lower odds of severe illness.

One year after infection, most patients showed no significant decline in lung function. However, those with advanced lung disease remain at higher risk and require close monitoring.

Experts stress that preventive care should focus on lung health rather than time since transplant. More research is needed for patients recently transplanted, as early post-transplant risks may differ.